Efficacy of an Encapsulated Probiotic Bifidobacterium infantis 35624 in Women with Irritable Bowel Syndrome

By P. Whorwell, L. Altringer, J. Morel, Yvonne Bond, D. Charbonneau, L. O’Mahony, B. Kiely, F. Shanahan, E. Quigley. American Journal of Gastroenterology, 2006

823 citations recorded by the source corpus.

Subfields: Food Science, Gastroenterology, Pharmacy

View Paper: https://www.semanticscholar.org/paper/9b6c117dc6671711159f6dd1c2dcf01ee2caa24c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Food Science

1. I. Zilber-Rosenberg
2. Eugene Rosenberg
3. K. Verbeke
4. Erwin G. Zoetendal

In Gastroenterology

1. M. Simrén
2. I. Zilber-Rosenberg
3. Eugene Rosenberg
4. B. Lacy
5. M. Pimentel

Citations in the corpus

• Dysbiosis of the gut microbiota in disease (2015, background): “on anxiety measures in clinical populations, including IBS (91, 92), schizophrenia (93), and rheumatoid arthritis”
• ACG Clinical Guideline: Management of Irritable Bowel Syndrome. (2020, background): “For example, in 1 study, more than 300 subjects were randomized to 1 of 3 doses of Bifidobacterium infantis 35,624 (10(6), 10(8), and 10(10) cfu/mL) or placebo (153).”
• Probiotics and prebiotics - Progress and challenges (2008, background): “As pain and discomfort are often symptoms of irritable bowel syndrome, it would be interesting to test B. infantis 35624, a probiotic shown to relieve abdominal pain in these patients (Whorwell et al., 2006).”
• The Hologenome Concept: Human, Animal and Plant Microbiota (2014, background): “…Synbiotics has shown promising results in altering the microbiota and reducing disease symptoms for inflammatory bowel disease (Dughera et al. 2007; Whorwell et al. 2006), methicillin-resistant enteritis (Kanamori et al. 2003), ulcers (Gotteland et al. 2005), atopic dermatitis in children (Farid…”
• Intestinal microbiota in functional bowel disorders: a Rome foundation report (2012, background): “At present, the strongest evidence is for Bifidobacterium infantis 35624 at a dose of 1310(8) cfu/day taken for at least 4 weeks.(224) It remains unclear who benefits from which variety of probiotic since there are many incompletely answered questions surrounding this therapeutic approach, including”
• Probiotics and the gut microbiota in intestinal health and disease (2010, background): “infantis , strain 35624, reduced abdominal pain, bloating, bowel dysfunction, incomplete evacuation, straining, and gas, compared with placebo after 4 weeks of therapy”
• Bowel Disorders. (2016, background): “Bifidobacterium infantis 35624 led to significant improvements in abdominal pain/discomfort, bloating/distention, and/or bowel movement difficulty compared with placebo in 2 randomized, placebo-controlled trials conducted in IBS patients.(55,56) A recent meta-analysis that included 43 clinical trial”
• Probiotics: definition, sources, selection, and uses. (2008, background): “For example, the efficacy of Bifidobacterium infantis 35264 has been documented at 10(8) cfu/day [16], whereas the recommended dose of VSL#3 (VSL Pharmaceuticals) is cfu/day, a 4-log cycle difference 12 1.”
• Antioxidant Properties of Probiotic Bacteria (2017, background): “It was able to promote antitumor immunity [32] and relieve irritable bowel syndrome in women [33].”